Fig. 2: Myeloid knockout of Wdfy3 augments CD4+ T cell activation by promoting MHC-II-mediated antigen presentation. | Nature Communications

Fig. 2: Myeloid knockout of Wdfy3 augments CD4+ T cell activation by promoting MHC-II-mediated antigen presentation.

From: Macrophage WDFY3 mitigates autoimmunity by enhancing efferocytosis and suppressing T cell activation in mice

Fig. 2

a Schematics of study design. Cre and Cre+ littermates were used to assess T cell activation. b The percentage of CD44highCD62Llow activated T cells in CD4+ and CD8+ T cells in the blood. n = 12 Cre vs 14 Cre+ mice and n = 11 Cre vs 13 Cre+ mice, respectively. c The percentage of CXCR3+ activated T cells in CD4+ and CD8+ T cells in the blood. n = 10 Cre vs 13 Cre+ mice. d The percentage of CD44highCD62Llow activated T cells in splenic CD4+ and CD8+ T cells. n = 6 Cre vs 8 Cre+ mice. e, f In vitro antigen presentation assay. BMDMs were pre-treated with synthetic ovalbumin (OVA) for 24 h, followed by incubating with splenic T cells isolated from OT-II or OT-I transgenic mice for 72 h to assess OVA323-339 or OVA257-264-specific activation of CD4+ T cells (OT-II mice) or CD8+ T cells (OT-I mice) that recognize OVA peptide residues when presented by the MHC-II or MHC-I molecules, respectively. The OT-II or OT-I mouse T cells were pre-labeled by carboxy-fluorescein succinimidyl ester (CFSE) to monitor the dilution of CFSE signal in daughter cells as T cells divide. n = 6 Cre vs 5 Cre+ mice. Effector T cell differentiation was assessed using a set of markers as indicated in the figures. n = 3 Cre vs 3 Cre+ mice. gl In vivo antigen presentation assay. gi Mice were immunized with OVA323-339 for 24 h before the injection of CFSE-labeled splenic CD4+ T cells from CD90.1+ OT-II mice. 72 h after injection, CFSE dilution in CD4+CD90.1+ blood and splenic T cells, and splenic T cell activation were assessed. n = 5 Cre vs 5 Cre+ mice for blood, and n = 5 Cre vs 7 Cre+ mice for spleen. jl Mice were immunized with OVA257-264 for 24 h before the injection of CFSE-labeled splenic CD8+ T cells from CD90.1+ OT-I mice. Seventy-two hours after injection, CFSE dilution in CD8+CD90.1+ blood and splenic T cells, and splenic T cell activation were assessed. For blood, n = 6 Cre vs 6 Cre+ mice; for spleen, n = 5 Cre vs 5 Cre+ mice (proliferation) and 6 Cre vs 6 Cre+ mice (T cell subsets). Data are shown as mean ± SEM. A two-tailed Student’s t-test was applied to all data.

Back to article page